All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2019-09-23T14:03:55.000Z

FDA grants the Investigational New Drug designation for PBCAR20A - a CAR T-cell therapy

Sep 23, 2019
Share:

Bookmark this article

On 16 September 2019, the US Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application for the off-the-shelf chimeric antigen receptor (CAR) T-cell therapy, PBCAR20A.  

PBCAR20A is a CD20-targeting genome-edited allogeneic CAR T-cell therapy candidate that can now be investigated for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). The phase 1/2a clinical trial is planned to start by the end of the year and aims to recruit patients with CLL, SLL, and NHL, including mantle cell lymphoma (MCL), for which the company has received Orphan Drug Designation. The initial report of this nonrandomized, open-label study is expected in 2020.

The approval is based on the preclinical data showing PBCAR20A efficacy in vivo against CD20+ tumor cells. The allogeneic CAR T-cells are created by inserting the CAR gene at the T-cell receptor (TCR) locus of T cells derived from healthy donors. The proprietary manufacturing platform allows fast manufacture of a consistent product, maintaining a high proportion of naïve and central memory CAR T-cells. The technology aims to prevent graft-versus-host disease.

This is the second off-the-shelf CAR T-cell IND product; PBCAR0191, an anti-CD19 CAR T-cell therapy, is currently being investigated in patients with relapsed/refractory (R/R) NHL and R/R B-cell precursor acute lymphoblastic leukemia (B-ALL).

  1. Precision BioSciences. Precision BioSciences announces FDA clearance of the IND for PBCAR20A, a CD20 targeting genome edited allogeneic CAR T therapy. Press release 16 September 2019. https://www.globenewswire.com/news-release/2019/09/16/1915788/0/en/Precision-BioSciences-Announces-FDA-Clearance-of-the-IND-for-PBCAR20A-a-CD20-Targeting-Genome-Edited-Allogeneic-CAR-T-Therapy.html. (Accessed on 23 September 2019)

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox